ACCESS AD Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment
- Coordinator
- Stichting Amsterdam Umc, Netherlands
- Runs
- 1 January 2026 to 31 December 2030
- Status
- Running
- EU funding
- €20.2m
- Total cost
- €37.6m
- Partners
- 36 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101253010
What the project is doing
In the project's own words, from its summary on CORDIS.
Alzheimer’s disease (AD) is a growing public health challenge in Europe’s ageing population. While Disease Modifying Therapies (DMTs) bring new therapeutic potential, fragmented care pathways, unequal diagnostic access, and healthcare limitations threaten their effectiveness and scalability. The Access AD Project is a collaborative initiative that exemplifies the public-private partnership model, bringing together government agencies and private sector organizations to addresses this unmet need by translating advanced diagnostics and monitoring approaches—such as blood-based and imaging biomarkers, digital and AI tools—into coordinated, equitable, and scalable care across real-world clinical settings in Europe.
The project aims to ensure that every individual with AD can access timely, personalized, and cost-effective care, regardless of geography or socioeconomic status. ACCESS-AD builds on local, national, and EU-level efforts to create an integrated, pan-European framework for optimized AD care. The project will achieve: 1) establish robust coordination and governance to ensure efficient delivery and stakeholder alignment; 2) connect and expand fragmented clinical and research data through a shared platform, linking registries and initiatives across Europe; 3) reduce diagnostic access barriers by improving standardized imaging, blood-based, and digital biomarkers for clinical use; 4) develop AI-driven tools to support personalized treatment decisions; 5) generate harmonized real-world evidence on DMTs and emerging therapies; 6) assess health-economic, regulatory, and patient-reported impacts; 7) engage patients, professionals, and policymakers to ensure adoption and sustainability.
Aligned with IHI Call 9.2, ACCESS-AD unites and engages diverse healthcare stakeholders and integrates needs and perspectives of individuals affected by dementia to deliver inclusive, connected, and personalized care centered around the AD patient. By translating innovation into real-world practice, the project will reduce inequalities, support health policy, and improve outcomes for AD patients across Europe.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Coordinator |
| Neurimmune SubOne AG | Schlieren | Switzerland | Participant |
| Positrigo AG | Zurich | Switzerland | Participant |
| Siemens Healthineers International AG | Zurich | Switzerland | Third party |
| Societe Des Produits Nestle SA | Vevey | Switzerland | Participant |
| Fakultni Nemocnice Motol a Homolka | Praha 5 | Czechia | Participant |
| Anavex Germany GmbH | Planegg | Germany | Participant |
| Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV | Bonn | Germany | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Klinikum Der Ludwig-Maximilians-Universitat Munchen | Munchen | Germany | Third party |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Neotiv GmbH | Magdeburg | Germany | Participant |
| Siemens Healthcare Diagnostics Products GmbH | Marburg | Germany | Third party |
| Siemens Healthineers AG | Forchheim | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | Thermi Thessaloniki | Greece | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
| Siemens Healthcare SL | Madrid | Spain | Third party |
| Universidad De Navarra | Pamplona | Spain | Participant |
| Pohjois-Savon Hyvinvointialue | Kuopio | Finland | Participant |
| Siemens Healthcare Private Limited | Vikhroli East | India | Associatedpartner |
| Alzheimer Europe | Senningerberg | Luxembourg | Participant |
| Amsterdam Umc Research BV | Amsterdam | Netherlands | Third party |
| Stichting International Registry for Alzheimers Disease and Other Dementias Foundation | Deventer | Netherlands | Participant |
| Helse Stavanger Hf | Stavanger | Norway | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Eisai Limited | Hatfield | United Kingdom | Participant |
| King's College London | London | United Kingdom | Participant |
| Muhdo Health Ltd | Ipswich | United Kingdom | Participant |
| National Institute for Health and Care Excellence | Manchester | United Kingdom | Participant |
| Siemens Healthcare Limited | Camberley | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Participant |
| University of Leicester | Leicester | United Kingdom | Participant |
| Gates Ventures Llc | Kirkland | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI